Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2009

01-10-2009 | Conference Paper

Triple negative breast cancer: clinicopathological characteristics and treatment strategies

Authors: Futoshi Akiyama, Hirotaka Iwase

Published in: Breast Cancer | Issue 4/2009

Login to get access

Abstract

Triple negative breast cancer (TNBC) is defined as a subtype that is negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. We introduce the theme of the special issue concerning clinicopathological characteristics and prospective treatment strategies of TNBC. This special issue consists of five conference papers that have been agreed on by the speakers and the commentator of the symposium of the 16th Annual Meeting of the Japanese Breast Cancer Society in September 2008 in Osaka.
Literature
1.
Iwase H, Yamamoto Y. Biological characteristics of triple negative breast cancer. Jpn J Breast Cancer. 2008;23(2):75–80.
2.
Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. javascript:AL_get(this, ‘jour’, ‘Breast Cancer.’). Breast Cancer. 2008;15(2):153–8.PubMedCrossRef
3.
Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen receptor-b evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008;26:3727–34.PubMedCrossRef
Metadata
Title
Triple negative breast cancer: clinicopathological characteristics and treatment strategies
Authors
Futoshi Akiyama
Hirotaka Iwase
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2009
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0140-x

Other articles of this Issue 4/2009

Breast Cancer 4/2009 Go to the issue

Conference Paper

Breast cancer risk assessment for possible tailored screening for Japanese women

Conference Paper

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics

Conference Paper

Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction

Conference Paper

Clinical significance of basal-like subtype in triple-negative breast cancer

Special Feature

Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer

Original Article

A cluster of microcalcifications: women with high risk for breast cancer versus other women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits